Investigating the role of selective pathway antagonists in highly self-renewing medulloblastoma subpopulations

Simple item page
dc.contributor.authorMcClelland, Robyn
dc.date.accessioned2015-06-01T19:31:48Z
dc.date.available2015-06-01T19:31:48Z
dc.date.issued2014-08-07
dc.description.abstractMedulloblastoma is the most common primary pediatric malignant brain tumour. It's highly infiltrative nature and ability to evade current therapies are associated with a high rate of metastasis and poor prognosis. Within medulloblastoma, there exist many cellular phenotypes, including some with a primitive phenotype that allows them to initiate or propogate tumours (brain tumour iniating or propagating cells). Recent work in this lab has identified CD271 as a marker for a more primitive phenotype within medulloblastoma. This project sought to examine two well-defined pathway antagonists effect on self-renewal abilities. Gamma-secretase inhibitors block the proteolytic processing of the CD271 receptor, while cyclopamine analogues inhibit the Shh pathway. These two pathway antagonists were used to examine effects on cells expressing, or overexpressing CD271, compared with cells not expressing CD271.en_US
dc.identifier.urihttp://hdl.handle.net/1993/30548
dc.language.isoengen_US
dc.rightsopen accessen_US
dc.subjectselective pathway antagonistsen_US
dc.subjectmedulloblastoma subpopulationsen_US
dc.titleInvestigating the role of selective pathway antagonists in highly self-renewing medulloblastoma subpopulationsen_US
dc.typeOtheren_US
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.17 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
College of Medicine - B.Sc. (Med) Projects